Urine test for prostate cancer; a genetic approach

An experimental new urine test can reveal if men with early prostate cancer will need aggressive therapy or can be left untreated but monitored, UK researchers say. Current prostate-specific antigen (PSA) blood tests cannot do this, meaning many men experience unnecessary worry, investigations and treatment.

The prostate urine risk (PUR) test looks for genetic markers to give a more accurate assessment. Trials in 537 patients suggest it can reliably sort men by risk. It is one of a number of new tests – including other urine-based ones, as well as blood tests and scans – that scientists are pursuing to improve prostate cancer detection.

A combination of checks rather than one single test may ultimately prove to be the best approach, experts say. Dr David Montgomery, from Prostate Cancer UK, said: "More research now needs to be done to see how accurate this is compared to the newer, non-invasive methods being offered, such as multi-parametric MRI scans."



Other news

Learning from history

Upcoming Events

Lab Innovations

NEC, Birmingham (Hall 12)
30-31 October 2019

British Society for Immunology Congress

Arena and Convention Centre, Kings Dock, Liverpool Waterfront, Liverpool L3 4FP
2-5 December 2019

The genomic and molecular revolution in microbiology: in technology we trust (or do we?).

RAF Museum, Hendon, London
14 May 2020

Clinical and Laboratory Haemostasis 2020

STEM/Atrium Conference Centre, Sheffield Hallam University
3-4 June 2020

Latest Issue

Pathology In Practice

Pathology In Practice

Oct 2019

Are you ready for the winter influenza season?

Register now to apply for regular copies of Pathology In Practice and free access to premium content, as well as our regular newsletters.